Health Science Department (DISSAL), University of Genoa, Italy; Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, Italia.
Azienda Ospedaliero Universitaria Careggi, University of Florence, Radiation Oncology Unit, Florence, Italy.
Oral Oncol. 2022 Apr;127:105773. doi: 10.1016/j.oraloncology.2022.105773. Epub 2022 Feb 24.
Immunotherapy represents an effective therapeutic option in the management of recurrent/metastatic head and neck squamous cell carcinoma, along with chemotherapy in metastatic disease or radiotherapy/re-irradiation for (locoregionally confined) recurrent disease. On the other hand, concomitant chemo-radiation remains the primary treatment modality in many patients with locally advanced disease. In spite of promising preclinical, it is difficult to clearly establish the role of immunotherapy in the upfront management of locally advanced head and neck squamous cell carcinoma and its integration with the standard of care. In this paper, we discuss/review the main results thus far available and outline some unanswered questions that might help design future clinical trials.
免疫疗法是复发性/转移性头颈部鳞状细胞癌的有效治疗选择，与转移性疾病中的化疗或（局部局限）复发性疾病中的放疗/再放疗联合使用。另一方面，在许多局部晚期疾病患者中，同步放化疗仍然是主要的治疗方式。尽管有很有前景的临床前研究，但免疫疗法在局部晚期头颈部鳞状细胞癌的初始治疗中的作用及其与标准治疗的整合仍难以明确确立。在本文中，我们讨论/回顾了迄今为止获得的主要结果，并提出了一些未解决的问题，这些问题可能有助于设计未来的临床试验。
